Published in Hepatitis Weekly, September 9th, 1996
Researcher Regino P. Gonzalez-Peralta and colleagues also found that increased HCV quasispecies heterogeneity is a marker associated with a poor response to interferon-(alpha) therapy.
Determination of quasispecies heterogeneity by conventional cloning and sequencing techniques is labor intensive and expensive. For this reason, analysis of a large number of clinical samples has been impractical, as are extensive clinical studies.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.